Activation and expansion of tumor-specific T cells and cytokine-induced killer cell

"Activation and expansion of tumor-specific T cells and CIK cells" is not a single molecular target or receptor but rather describes an immunotherapeutic process. This process involves stimulating patient-derived immune effector cells—specifically, tumor-reactive T lymphocytes and cytokine-induced killer (CIK) cells—using various cytokines such as IL‑2, IFN‑γ, anti-CD3 antibody, and IL‑1. The goal is to generate large numbers of potent cytotoxic lymphocytes that can recognize and kill cancerous or infected target cells in an MHC-independent manner[2][3]. CIK cells are characterized by both T-cell (CD3+) and natural killer cell-like phenotypes (CD56+), enabling them to lyse a broad range of tumors without harming healthy tissue[2][4]. This approach is used in adoptive cellular immunotherapy for cancer but does not refer to a discrete protein or gene product; therefore it should not be classified as a canonical therapeutic target molecule or receptor. This entry is considered incorrect as a "target" because it refers to an immunological strategy/process rather than a specific molecular entity suitable for structured drug-target databases.

Other names

Tumor-specific T cell activationCIK cell activationExpansion of tumor-reactive T cellsCytokine-induced killer (CIK) cell therapy

Ex vivo stimulation with cytokines to expand and activate immune effector cells capable of MHC-unrestricted cytotoxicity against tumor cells[2][3].